A number of pharmacologic therapies are available or in clinical development to treat Clostridioides difficile infection (CDI), which is the No. 1 cause of nosocomial infections in American hospitals.
Lukas Martin, PharmD, BCCCP, a clinical pharmacist at St. Elizabeth Healthcare in Edgewood, Ky., noted that the two major drug treatments for CDI are the antibiotics vancomycin and fidaxomicin (Dificid, Merck). The 2018 updated CDI guideline from the Infectious Diseases Society of